Aquestive Therapeutics (AQST) Accounts Payables (2017 - 2026)

Aquestive Therapeutics' Accounts Payables history runs 10 years deep, the most recent figure standing at $11.9 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 3.18% year-over-year to $11.9 million; the TTM figure through Mar 2026 stood at $11.9 million (down 3.18% YoY), while the FY2025 annual figure was $29.9 million, up 190.29% from the prior year.
• Accounts Payables was $11.9 million for Q1 2026 at Aquestive Therapeutics, down from $29.9 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $29.9 million in Q4 2025 to a low of $5.7 million in Q2 2024.
• Historically, Accounts Payables has averaged $11.3 million across 5 years, with a median of $10.5 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables plunged 46.71% in 2024, then soared 190.29% in 2025.
• A 5-year view of Accounts Payables shows it stood at $9.9 million in 2022, then decreased by 10.26% to $8.9 million in 2023, then climbed by 15.25% to $10.3 million in 2024, then jumped by 190.29% to $29.9 million in 2025, then tumbled by 60.19% to $11.9 million in 2026.
• The last three Accounts Payables figures came in at $11.9 million (Q1 2026), $29.9 million (Q4 2025), and $10.9 million (Q3 2025), per Business Quant data.